Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lexaria Bioscience ( (LEXX) ) just unveiled an announcement.
At its annual shareholder meeting held on January 27, 2026, Lexaria Bioscience saw 8,380,389 shares represented in person or by proxy, accounting for 37.71% of its issued share capital as of the December 1, 2025 record date. Shareholders approved the election of seven directors, the appointment of Malone Bailey LLP as auditors, and the ratification of the directors’ lawful actions over the past year, consolidating current leadership and governance structures and signaling continued support for the company’s existing oversight and auditing arrangements.
The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Average Trading Volume: 638,364
Technical Sentiment Signal: Sell
Current Market Cap: $20.26M
For a thorough assessment of LEXX stock, go to TipRanks’ Stock Analysis page.